Search Results
Your search for ,amp matches 4215 pages
Showing 1351 - 1400Tackling a Growing Need: Options After CAR T-Cell Therapy for Lymphoma
For aggressive B-cell lymphomas, chimeric antigen receptor (CAR) T-cell therapy saves lives, but relapse remains common, and a second-line standard of care is lacking. During the 2021 Pan Pacific Lymphoma Conference, Grzegorz (Greg) S. Nowakowski, MD, Professor of Medicine and Oncology, Lymphoma...
A Look at Tomorrow’s CAR T-Cell Therapy Today
Some of the most impressive data on chimeric antigen receptor (CAR) T-cell therapy have come from studies conducted in China. Attendees at the 2021 Pan Pacific Lymphoma Conference heard from one of the leading Chinese investigators, Peihua (Peggy) Lu, MD, of Lu Daopei Hospital, who described the...
Two Studies Show Health-Care Costs May Impact Follow-up Care After Cancer Screening
Eleven years ago this month, the scans and exams that hold the most power to spot the early signs of cancer became available for free to many American adults through the passing of the Affordable Care Act. Now, two new studies show that when those screening tests reveal potentially troubling signs, ...
Improved Health Insurance Coverage, Access to Care May Lessen Racial/Ethnic Disparities in Childhood Cancer Survival
A new study published by Jingxuan Zhao, MPH, and colleagues in Cancer Epidemiology, Biomarkers & Prevention found racial/ethnic disparities in survival among newly diagnosed patients with childhood cancers in the United States, and that area-level socioeconomic status and health insurance...
CASSIOPEIA Part 2: Maintenance Daratumumab After Initial Therapy for Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has shown significantly prolonged progression-free survival with maintenance daratumumab vs observation following induction and consolidation with or without...
Classifying EGFR Mutations by Structure and Function May Help to Match Patients With NSCLC to More Effective Treatments
Researchers have discovered that grouping EGFR mutations by structure and function provides an accurate framework to match patients with non–small cell lung cancer (NSCLC) to the right drugs. The findings, published by Robichaux et al in Nature, identify four subgroups of mutations and introduce a...
The Wistar Institute Recruits Vaccine Researcher Amelia Escolano, PhD, and Immunologist Nan Zhang, PhD, as Assistant Professors
The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, has appointed Amelia Escolano, PhD, and Nan Zhang, PhD, as Assistant Professors. Dr. Escolano’s research focuses on the development of novel vaccine approaches against highly mutating ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Brunei Darussalam
With a population under half a million people, Brunei Darussalam is a small equatorial nation in Southeast Asia. Bordered by the South China Sea on the north, Brunei Darussalam is surrounded on all other sides by Malaysia, which separates the nation into two noncontiguous parts. Nearly two-thirds...
Pembrolizumab and Lenvatinib in Advanced Endometrial Carcinoma
On July 21, 2021, pembrolizumab in combination with lenvatinib was granted regular approval for treatment of patients with advanced endometrial carcinoma that is not microsatellite instability–high or mismatch repair–deficient who have disease progression following prior systemic therapy in any...
Lenvatinib Plus Pembrolizumab for First-Line Treatment of Advanced Renal Cell Carcinoma
On August 10, 2021, the combination of lenvatinib plus pembrolizumab was approved for first-line treatment of adults with advanced renal cell carcinoma.1,2 Supporting Efficacy Data Approval was based on findings from the three-arm, open-label, phase III CLEAR trial (Study 307/KEYNOTE-581;...
Disaster Assistance: Resources Available for Cancer Care Physicians, Patients Impacted by Hurricane Ida
ASCO has a list of resources and information to support cancer care providers and patients affected by natural disasters such as Hurricane Ida. The resources include materials from the Centers for Medicare & Medicaid Services, emergency contact and preparedness information, and information on...
ASCO Applauds Administration Decision to Withdraw Most Favored Nation Model
“The Association for Clinical Oncology (ASCO) commends the Biden Administration for proposing to rescind the Most Favored Nation (MFN) model from consideration. ASCO has consistently opposed the ill-advised MFN model, as it would have had a devastating impact on people with cancer. “The proposed...
Expert Point of View: Gordon Cook, MBChB, PhD and Sagar Lonial, MD
The OPTIMUM/MUKnine1 and FORTE2 updates were discussed at the 2021 ASCO Annual Meeting by Gordon Cook, MBChB, PhD, Clinical Director of the National Institute for Health Research In Vitro Diagnostics Cooperative and the Clinical Trials Unit in Hematology of the University of Leeds, United Kingdom....
Myeloma Trial Updates: Focus on High-Risk Patients and Measurable Residual Disease Negativity
Newly diagnosed patients with multiple myeloma deemed at high risk for disease progression may achieve sustained measurable residual disease (MRD) negativity with newer regimens and transplantation, and this may translate into longer progression-free survival. That’s the key take-away message from...
Belzutifan for Cancers Associated With von Hippel-Lindau Disease
On August 13, 2021, belzutifan, a hypoxia-inducible factor inhibitor, was approved for treatment of adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors but do not...
ASCO 2021: Roundup of Studies You May Have Missed
As ASCO Annual Meeting attendees know by now, clinicians don’t have to be at McCormick Place to hear practice-changing findings and forward-looking advances in the field of oncology. Interesting content was no exception at the 2021 conference, so in addition to covering the biggest news from the...
Lymphoid Malignancies: What’s Next for Antibody-Drug Conjugates?
Antibody-drug conjugates are improving outcomes of patients with lymphoma, often those who have exhausted treatment options after chimeric antigen receptor (CAR) T-cell therapy. Four available antibody-drug conjugates are in the clinic, with brentuximab vedotin moving into the front-line...
Bispecific Antibodies Find a Place in B-Cell Lymphoma Treatment
In relapsed or refractory B-cell lymphomas, bispecific T-cell engager antibodies are finding a place in the treatment algorithm, said Christopher Flowers, MD, MS, FASCO, Professor and Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston. At the...
BRAF-Mutant Colorectal Cancer: Latest Findings for Targeted Treatment
The phase II ANCHOR CRC study, the largest prospective study of BRAF inhibitor–based therapy as first-line treatment of metastatic colorectal cancer, has met its primary endpoint, with 47.8% of patients with metastatic colorectal cancer responding to first-line treatment with encorafenib,...
Ruxolitinib Granted FDA Approval for Chronic Graft-vs-Host Disease
On September 22, the U.S. Food and Drug Administration approved ruxolitinib (Jakafi), a JAK inhibitor, for the treatment of chronic graft-vs-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older. REACH3 Efficacy was...
COSMIC-021: Cabozantinib Plus Atezolizumab for Advanced Renal Cell Carcinoma
In the phase Ib COSMIC-021 trial reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues found that the combination of cabozantinib and atezolizumab produced durable responses in patients with advanced renal cell carcinoma (RCC). Study Details One hundred and two...
Adjuvant Pembrolizumab for High-Risk Stage II Melanoma: Efficacy and Safety Examined
Adjuvant pembrolizumab reduced the risk of disease recurrence in adults and children aged 12 years and older with high-risk stage II melanoma vs placebo, according to a late-breaking interim analysis of the phase III KEYNOTE-716 trial presented by Jason J. Luke, MD, and colleagues at the European...
FDA Grants Accelerated Approval to Mobocertinib for Patients With Metastatic NSCLC and EGFR Exon 20 Insertion Mutations
� On September 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mobocertinib (Exkivity) for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations (as detected by an FDA-approved test) whose disease has...
Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better
In advanced ovarian cancer, the duration of maintenance bevacizumab should remain 15 months, according to the European multicenter phase III ENGOT/GCIG trial. These results were presented during the 2021 ASCO Annual Meeting by Jacobus Pfisterer, MD, PhD, of the AGO Study Group and Gynecologic...
Hormonal Intrauterine Device Under Study for Managing Early Endometrial Cancer
Disease regression was observed in 82% of women with endometrial hyperplasia with atypia and 43% of women with endometrial cancer after treatment for 6 months with a hormonal intrauterine device, in a phase II study reported during the virtual edition of the Society of Gynecologic Oncology (SGO)...
Novel Treatments Show Activity in Advanced Cervical Cancer
The treatment of recurrent or metastatic cervical cancer has not changed much in recent years, but according to preliminary trials presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, checkpoint inhibitors and antibody-drug conjugates may become new options. In the...
Expert Point of View: Ursula A. Matulonis, MD and Konstantin Zakashansky, MD
Perspectives on ARIEL4 were provided for The ASCO Post by the invited discussant Ursula A. Matulonis, MD, Professor of Medicine, Harvard Medical School, and Chief of Gynecologic Oncology and the Brock Wilson Family Chair at Dana-Farber Cancer Institute, Boston, and Konstantin Zakashansky, MD,...
Phase III ARIEL4 Trial Evaluates Rucaparib’s Benefit in BRCA-Mutated Relapsed Ovarian Cancer
In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP (poly [ADP-ribose] polymerase) inhibitor rucaparib led to a significant improvement in progression-free survival compared with standard-of-care chemotherapy, according to the results of the international phase ...
Expert Point of View: Thomas Herzog, MD
The discussant of the fuzuloparib abstract at the Society of Gynecologic Oncology meeting was Thomas Herzog, MD, Deputy Director of the University of Cincinnati (UC) Cancer Center and Professor of Obstetrics and Gynecology at the UC College of Medicine. He said that these data have already led to...
Sotorasib: Subgroup Analysis of Phase II Trial Shows Activity With KRAS Inhibitor in Lung Cancer
The KRAS-specific inhibitor sotorasib achieved responses in patients with KRAS G12C–mutated non–small lung cancer (NSCLC) who had experienced disease progression on platinum-based chemotherapy, immunotherapy, or both treatments. The objective response rate was 37.1%, and responses extended to all...
ADAPT Trial: ‘Excellent’ Outcomes Reported With Neoadjuvant Dual HER2 Therapy in Breast Cancer
The first overall survival analysis of the WGS-ADAPT HER2+/HR– study, which evaluated neoadjuvant therapy in patients with hormone receptor–negative, HER2-positive disease, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or with the chemotherapy-free regimen of...
Fixed-Dose, First-Line Ibrutinib/Venetoclax Combination Achieves Durable Remissions in CLL
The combination of fixed-duration, first-line treatment with ibrutinib plus venetoclax achieved complete responses in more than half of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), based on the primary analysis of the fixed-dose cohort of the phase II CAPTIVATE ...
Lifileucel After Disease Progression in Metastatic Melanoma: Durable Responses Achieved in Phase II Trial
Despite the fact that we have made significant progress in metastatic melanoma with immune checkpoint inhibitors—now the standard of care—most patients experience disease progression and are left without approved treatments. There is a need for newer treatments with clinical benefit. Lifileucel, an ...
KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
Expert Point of View: Anthony TC Chan, MD
The invited discussant of the JUPITER-02 study was Anthony TC Chan, MD, the Li Shu Fan Medical Foundation Professor of Clinical Oncology at Hong King Cancer Institute and Sir YK Pao Centre for Cancer at the Chinese University of Hong Kong. He noted that anti–PD-1/L1 therapies are at the forefront...
Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC
Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the ...
Survey Examines Oncology Clinician Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer
Less than half of community oncologists surveyed indicated that they use biomarker testing to guide patient discussions compared with 73% of academic clinicians, according to a report by Boehmer et al presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World...
Conquer Cancer Names Inaugural Recipients of ASCO Registry Research Grants
Conquer Cancer, the ASCO Foundation, is pleased to announce the recipients of its 2021 ASCO Registry Research Grants. Conquer Cancer established the ASCO Registry Research Grant to support research using data derived from the ASCO Survey on COVID-19 in Oncology Registry (the “ASCO Registry”). The...
High Prevalence of Germline BRCA Mutations in Indian Women With Ovarian Cancer
In a prospective cross-sectional study reported in JCO Global Oncology, Sudeep Gupta, MBBS, MD, DM, of Tata Memorial Centre, and colleagues found that Indian women with ovarian cancer not selected for study based on clinical factors had a high prevalence of germline pathogenic or likely pathogenic...
Adding LuPSMA to Standard Care Improves Outcomes in Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Oliver Sartor, MD, of the School of Medicine, Tulane University, and colleagues, the phase III VISION trial has shown prolonged progression-free and overall survival with lutetium-177–PSMA-617 (LuPSMA) radioligand therapy plus standard care vs...
Cancer Is Trying to Steal My Body, but I Will Not Allow It to Steal My Joy
Until I was diagnosed with HER2-positive, estrogen receptor–positive/progesterone receptor–positive de novo metastatic breast cancer in 2009, I didn’t realize that Black women could get the disease. Although my mother died of metastatic breast cancer 5 years earlier when she was 65, she was the...
Maintained Benefit of Apalutamide Plus Androgen-Deprivation Therapy Shown in Metastatic Castration-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim N. Chi, MD, of BC Cancer and Vancouver Prostate Centre, and colleagues, the final overall survival analysis of the phase III TITAN trial showed significant benefit of apalutamide plus androgen-deprivation therapy vs placebo plus...
Pembrolizumab Combined With Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
On May 5, 2021, pembrolizumab was granted accelerated approval for use in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
“Progress lies not in enhancing what is, but in advancing toward what will be.” —Khalil Gibran The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held virtually...
Pembrolizumab for High-Risk, Early-Stage Triple-Negative Breast Cancer
On July 26, 2021, pembrolizumab was approved for high-risk, early-stage, triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and continued as adjuvant treatment.1 Pembrolizumab was also granted regular approval in combination with chemotherapy for locally...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in South Africa
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in South Africa. The aim of this special feature is to highlight the global cancer burden for various countries of...
Study Finds Low-Poverty U.S. Counties May Eliminate Cervical Cancer 14 Years Earlier Than High-Poverty Counties
About 14,500 new cases of invasive cervical cancer are diagnosed each year in the United States and nearly 4,300 women die from the disease. Studies show that those living in higher-poverty areas experience higher rates of morbidity and mortality from many preventable cancers, including cervical...
Assumptions, Data … and More Questions!
I read with great interest the results from the phase II ZUMA-12 study of axicabtagene ciloleucel, presented during the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 But the results raised several questions for me. Axicabtagene ciloleucel, an autologous anti-CD19...
Phase II Trial Evaluates Oncolytic Coxsackievirus A21 for Unresectable Advanced Melanoma
In a phase II trial reported in the Journal of Clinical Oncology, Robert H.I. Andtbacka, MD, and colleagues found that intratumoral injection of the oncolytic RNA virus Coxsackievirus A21 (V937) was well tolerated and produced responses in some patients with unresectable stage III or stage IV...
